Acumen. Leadership. Expertise.

The Astute Medical team has extensive industry experience and insights on validation of biomarkers. Our senior leadership team offers expertise in developing, manufacturing and commercialization of products in the health care field.

McPherson leads scientific decisions involving prognostic biomarker validation for Astute Medical.

Hughes leads regulation of our prognostic biomarker validation and product development processes.

Dr. Ravi Vijayendran is a leader and expert in the development, technology transfer, and manufacturing of rapid test and point-of-care in-vitro diagnostic products.

Joe Anderberg, Ph.D., has over 30 years’ experience in research and development.

The Astute Medical Management Team Click photos to see a biography

Paul H. McPherson, PhD | Chief Executive Officer, Chief Scientific Officer, Co-Founder
Karin A. Hughes, PhD | VP of Clinical, Quality and Regulatory Strategy
Ravi Vijayendran | VP of Product Development and Manufacturing
Joe Anderberg | VP of Emerging Technologies

Paul H. McPherson, PhD Chief Executive Officer, Chief Scientific Officer, Co-Founder

Paul H. McPherson, Ph.D., is the co-founder as chief scientific officer and currently serves as chief executive officer of Astute Medical, Inc. (a subsidiary of bioMérieux, Inc.), a San Diego-based company identifying and validating new protein biomarkers to serve as the basis for novel diagnostic tests, including the first product (NEPHROCHECK® Test) cleared by the FDA for risk assessment for acute kidney injury.

Dr. McPherson has over 25 years’ experience in research and development. He has over 25 issued U.S. patents in areas ranging from immunoassay platforms to novel biomarker content in a variety of disease areas.

Prior to co-founding Astute Medical in 2007, Dr. McPherson was vice president of research and development at Biosite Inc., a leading diagnostics company acquired by Inverness Medical Innovations. During his 14-year tenure at Biosite, Dr. McPherson led the company’s 85-person research and development team in its hunt for new biomarkers for disease. The team successfully developed and launched eight FDA-cleared products, which included novel diagnostics for congestive heart failure and the first quantitative point-of-care troponin test for myocardial infarction. He played a key role in the development and commercialization of Biosite’s Triage® Meter Platform and the Triage® family of point-of-care immunoassay products.

Dr. McPherson was a post-graduate research physicist at the University of California, San Diego, where he conducted and published research on the biophysics of photosynthesis.

He earned a doctorate in physics (biophysics) from the University of California, San Diego and a bachelor’s in physics from the University of California, Santa Cruz.

Karin A. Hughes, PhD VP of Clinical, Quality and Regulatory Strategy

Dr. Hughes has over 20 years’ experience in the in vitro diagnostics and life science industries. Karin has served on the Board for Directors for the Association of Medical Diagnostics Manufacturers (AMDM) for several years, holding various board titles, including President. Prior to joining Astute, Karin was the Director of Regulatory Affairs for Biosite Incorporated, an Inverness Medical Innovations company, also located in San Diego, CA. There, Karin managed a team of Regulatory Affairs professionals and had global responsibility for the development and implementation of regulatory strategies for product registrations while ensuring regulatory compliance for the Cardiology, Drugs-of-Abuse and Oncology Strategic Business Units. Previous positions include Director of Marketing for the Calbiochem® brand of Merck, KGaA and Vice President of R&D for Prolinx, Inc, a Seattle start-up. Karin holds a B.S. degree in Chemistry from Hartwick College, Oneonta, NY and a Ph.D. in Chemistry from the University of Virginia.

Ravi Vijayendran VP of Product Development and Manufacturing

Dr. Ravi Vijayendran is a leader and expert in the development, technology transfer, and manufacturing of rapid test and point-of-care in-vitro diagnostic products. He has 15 years of experience in the research and development of in-vitro diagnostic and life science products. Dr. Vijayendran leads the development and oversees the manufacturing of Astute Medical’s NephroCheck and other innovative, biomarker-based diagnostic products.

Prior to joining Astute Medical, Dr. Vijayendran held positions at Biosite, Inc. and Alere, Inc., where he led the technical development of cardiovascular immunodiagnostic products from research and development through product commercialization. He also previously held a scientific position with Caliper Technologies, Corp., developing microfluidic products for the life sciences. Dr. Vijayendran holds a doctorate degree in chemical engineering from the University of Illinois and a bachelor’s degree in chemical engineering from Cornell University.

Joe Anderberg VP of Emerging Technologies

Joe Anderberg, Ph.D., has over 30 years’ experience in research and development. He has over 50 issued and pending U.S. patents in areas ranging from immunoassay methods and readers to novel biomarker content.

As an early team member of Astute Medical Inc., Dr. Anderberg built the foundations of Astute’s discovery engine.

Prior to joining Astute Medical in 2008, Dr. Anderberg was Sr. Director of Quantitative R&D at Biosite Inc., a leading diagnostics company acquired by Inverness Medical Innovations for $1.7 billion. During his 11 years at Biosite, Dr. Anderberg’s primary role was the development and commercialization of Biosite’s Triage® Meter Platform. He also was a key member of the Biomarker Discovery Team, and invented an innovative assay technology.

Prior experience includes the development of SQUID magnetometer based research instruments at Conductus Inc. and metrology tools for the X-ray Mask and Electron Beam Exposure group at AT&T Bell Laboratories.

He earned a doctorate in physics from the University of California, San Diego and a bachelor’s in physics from Harvey Mudd College.